The outstanding work of MS specialist nurses, neurologists, allied health professionals and multi-disciplinary teams from across the UK was celebrated at the third annual QuDoS in MS recognition programme.
- Shortage of neurology services
- Diet affects gut bacteria and modulates immune system
- Cognitive symptoms in early-stage MS
- High number of people with MS turned down for PIP
- Biotin may affect medical tests
- Mark Lewis and stem cells
- Self-management may help mood
- CCSVI trial disappointing
- Why smoking is bad for people with MS
- Ocrevus licensed for relapsing and progressive MS
- Gilenya effective for children with MS
- Social care failing people with disabilities
- Wii a useful way to exercise
The European Medicines Agency recommends licensing for ocrelizumab (Ocrevus) for treating active relapsing and early primary progressive MS.
NHS England and Merck have reached an agreement that people eligible for treatment can access Mavenclad (cladribine) immediately.
Reports of studies presented at the ECTRIMS meeting that took place from 25-28 October 2017. Topics include research into existing and new drugs for relapsing and progressive MS and lifestyle factors in MS.
- Ibudilast trial show benefit in progressive MS
- Gilenya effective as treatment for teens with MS
- Zinbryta liver damage restrictions
- Having other health conditions delays MS diagnosis
- The benefits of running for a woman with MS
We are thrilled to announce that our corporate partner Constructive Space has raised an incredible £17,288 to support people living with MS.